Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study
A gradually higher prevalence of metabolic syndrome among PLWH occurred with changes from RPV/TDF/FTC to RPV/TAF/FTC but plateaued beyond 2 years. However, fewer drugs for dyslipidemia, diabetes, and hypertension were prescribed within the first year after changing cART.
Authors
- Meng‐Yu Ke
- Ping‐Feng Wu (ORCID: https://orcid.org/0000-0002-5821-1260)
- Hsin‐Pai Chen (ORCID: https://orcid.org/0000-0002-5956-0526)
- Hsi‐Hsun Lin
- Po‐Hsun Huang (ORCID: https://orcid.org/0000-0003-1584-6749)
Institutions
- National Yang Ming Chiao Tung University (TW)
- Taipei Veterans General Hospital (TW)
- I-Shou University (TW)
Publication Details
- Journal
- Health Science Reports
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/hsr2.70275
- Citations
- 1
- Primary Topic
- HIV-related health complications and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.69
Funders
- Taipei Veterans General Hospital